• Andrea Schmidts, Maria Ormhøj, Bryan D Choi, Allison O Taylor, Amanda A Bouffard, Irene Scarfò, Rebecca C Larson, Matthew J Frigault, Kathleen Gallagher, Ana P Castano, Lauren S Riley, Maria L Cabral, Angela C Boroughs, Rubí M-H Velasco Cárdenas, Wolfgang Schamel, Jing Zhou, Sean Mackay, Yu-Tzu Tai, Kenneth C Anderson, and Marcela V Maus.
• Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
• Blood Adv. 2019 Nov 12; 3 (21): 3248-3260.

AbstractChimeric antigen receptor (CAR) T cells (CARTs) have shown tremendous potential for the treatment of certain B-cell malignancies, including patients with relapsed/refractory multiple myeloma (MM). Targeting the B-cell maturation antigen (BCMA) has produced the most promising results for CART therapy of MM to date, but not all remissions are sustained. Emergence of BCMA escape variants has been reported under the selective pressure of monospecific anti-BCMA CART treatment. Thus, there is a clinical need for continuous improvement of CART therapies for MM. Here, we show that a novel trimeric APRIL (a proliferation-inducing ligand)-based CAR efficiently targets both BCMA+ and BCMA- MM. Modeled after the natural ligand-receptor pair, APRIL-based CARs allow for bispecific targeting of the MM-associated antigens BCMA and transmembrane activator and CAML interactor (TACI). However, natural ligands as CAR antigen-binding domains may require further engineering to promote optimal binding and multimerization to adequately trigger T-cell activation. We found that using a trimeric rather than a monomeric APRIL format as the antigen-binding domain enhanced binding to BCMA and TACI and CART activity against MM in vitro and in vivo. Dual-specific, trimeric APRIL-based CAR are a promising therapeutic approach for MM with potential for preventing and treating BCMA escape.© 2019 by The American Society of Hematology.

33 keywords...

hide…